首页> 外文期刊>European Journal of Pharmacology: An International Journal >Comparative antiarrhythmic efficacy of amiodarone and dronedarone during acute myocardial infarction in rats.
【24h】

Comparative antiarrhythmic efficacy of amiodarone and dronedarone during acute myocardial infarction in rats.

机译:胺碘酮和决奈达隆在大鼠急性心肌梗死中的抗心律失常疗效比较。

获取原文
获取原文并翻译 | 示例
           

摘要

The effects of dronedarone, a non-iodinated derivative of amiodarone, on ventricular tachycardia and ventricular fibrillation post-myocardial infarction are not well established. Fifty-five Wistar rats were randomly allocated to a 2-week oral treatment with either vehicle (n=18), amiodarone (30 mg/kg, n=20), or dronedarone (30 mg/kg, n=17). After acute coronary artery ligation, a single-lead electrocardiogram was continuously recorded for 24 h and episodes of ventricular tachycardia/fibrillation as well as mortality rates were analysed. Monophasic action potential recordings were obtained from the left ventricular epicardium at baseline and 24 h post-myocardial infarction. Thyroid hormones and catecholamines were measured using radioimmunoassay. Thyroid function was similar in the 3 groups. Compared to controls, amiodarone and dronedarone equally decreased the number of ventricular tachycardia/fibrillation episodes by approximately 75%. Both agents prevented the increase in monophasic action potential duration and in beat-to-beat variation. Norepinephrine levels were lower only after amiodarone treatment. Despite the observed antiarrhythmic effect, total mortality did not differ between groups (38.8% in controls, 30.0% in the amiodarone group and 58.8% in the dronedarone group), because of excess bradyarrhythmic mortality in both drug groups that reached significance in the dronedarone group. Dronedarone and amiodarone display similar antiarrhythmic efficacy post-myocardial infarction, partly by preventing repolarization inhomogeneity. However, dronedarone increases bradyarrhythmic mortality possibly secondary to its negative inotropic effects.
机译:胺碘酮的非碘代衍生物决奈达隆对心肌梗死后室性心动过速和心室纤颤的作用尚不明确。将55只Wistar大鼠随机分配至为期两周的口服治疗,分别用赋形剂(n = 18),胺碘酮(30 mg / kg,n = 20)或决奈达隆(30 mg / kg,n = 17)。急性冠状动脉结扎后,连续24h记录单导联心电图,并分析心室心动过速/纤颤发作和死亡率。在基线和心肌梗死后24小时从左心室心外膜获得单相动作电位记录。使用放射免疫分析法测定甲状腺激素和儿茶酚胺。 3组的甲状腺功能相似。与对照组相比,胺碘酮和决奈达隆平均减少了约75%的室性心动过速/颤动发作次数。两种试剂均防止单相动作电位持续时间和逐搏变化的增加。去甲肾上腺素水平只有在胺碘酮治疗后才降低。尽管观察到了抗心律不齐的效果,但各组间的总死亡率没有差异(对照组为38.8%,胺碘酮组为30.0%,决奈达隆组为58.8%),这是因为两个药物组的过慢性心律失常死亡率均在决奈达隆组中达到了显着水平。决奈达隆和胺碘酮在心肌梗死后显示出相似的抗心律不齐功效,部分是通过防止复极不均一性。但是,决奈达隆可能会增加负性肌力作用,从而增加心律失常的死亡率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号